Format

Send to

Choose Destination
Expert Opin Pharmacother. 2016 Oct;17(14):1963-8. doi: 10.1080/14656566.2016.1225725. Epub 2016 Aug 29.

Sonidegib for the treatment of advanced basal cell carcinoma.

Author information

1
a Department of Dermatology , University Hospital Zurich , Zurich , Switzerland.
2
b Centre of Dermatovenereology , Vilnius University , Vilnius , Lithuania.

Abstract

INTRODUCTION:

Advanced and metastatic basal cell carcinomas (BCCs) are rare but still present a severe medical problem. These tumors are often disfiguring and impact the quality of life by pain or bleeding. Based on discovery of the hedgehog (Hh) signaling pathway and its role in the pathogenesis of BCCs, smoothened (SMO) inhibitors have been developed with Sonidegib being the 2nd in class. It is the only Hh pathway inhibitor investigated in a randomized trial accompanied by pharmacodynamic investigations. Also, the disease assessment criteria applied were more stringent than those used in trials of 1st developed SMO inhibitor - vismodegib, and required annotated photographs, MRI as well as multiple biopsies in case of regression.

AREAS COVERED:

All available papers from Medline and the abstracts of the most important dermato-oncology meetings were included.

EXPERT OPINION:

Sonidegib is a promising medication for advanced BCC and other malignancies, driven by Hh signaling. It presents favorable pharmacokinetic properties and causes class specific toxicity with dose dependent adverse events in muscular and taste bud homeostasis, gastrointestinal symptoms and hair growth. Early after treatment initiation, it impacts the immunesusceptibility of the tumor lesions. Sonidegib deserves further development in combination with other drugs or antibodies, or alternative dosing schedules.

KEYWORDS:

Basal cell carcinoma; Hh inhibitor; SMO inhibitor; sonidegib

PMID:
27538055
DOI:
10.1080/14656566.2016.1225725
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center